A High HAQ at Baseline in Early RA Is a Bad Sign
A Closer Look at Antibodies in RA: How Anti-Citrullinated Protein Antibodies, Anti-Modified Protein Autoantibodies & Rheumatoid Factor Activity Overlap
Long-Term Safety of Baricitinib for RA
Upadacitinib Safety Similar to Other Jakinibs for RA
1 Step Closer: Study Examines Factors That Lead to RA in Hope of Developing Prevention Strategies
Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments
RA Patients Taking Either 15 mg or 30 mg Dose of Upadacitinib Experience Improvement
For RA Patients, Functional Disability May Precede Diagnosis
Biologics May Prevent Cardiovascular Events in RA Patients
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 28
- Next Page »